ResMed director Nicole Mowad-Nassar reports 536-share RSU award

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported an insider equity award for director Nicole Mowad-Nassar on a Form 4. On 11/20/2025, she received 536 shares of ResMed common stock as a grant of restricted stock units at a stated price of $0 per share, reflecting a stock-based award rather than an open-market purchase. Following this transaction, she beneficially owned 777 shares directly.

The filing notes that these restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders held in the year following the grant date. This is a routine director compensation transaction and does not involve any derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mowad-Nassar Nicole

Role Director

Type	Security	Shares	Price	Value
Grant/Award	ResMed Common Stock	536	$0.00	--

Holdings After Transaction: ResMed Common Stock — 777 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mowad-Nassar Nicole

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	11/20/2025		A(1)		536	A	$0	777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date.

	Nicole Mowad-Nassar, director	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) report in this Form 4?

ResMed reported that director Nicole Mowad-Nassar received a grant of 536 restricted stock units of ResMed common stock on 11/20/2025.

Who is the reporting person in ResMed (RMD)'s latest Form 4 filing?

The reporting person is Nicole Mowad-Nassar, who is identified as a director of ResMed Inc.

How many ResMed (RMD) shares does the director own after this transaction?

After the reported restricted stock unit award, the director beneficially owned 777 shares of ResMed common stock in direct ownership.

What are the vesting terms of the ResMed (RMD) restricted stock units?

The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date.

Was there any exercise price for the ResMed (RMD) RSU award?

The reported transaction shows a price of $0 per share, which is typical for restricted stock unit awards granted as compensation rather than open-market purchases.

Does this ResMed (RMD) Form 4 include any derivative securities transactions?

No. The Table II section for derivative securities shows no derivative securities acquired, disposed of, or beneficially owned in this report.